US-based pharmaceutical consulting company J & D Pharmaceuticals LLC announced on Thursday that its investigational therapy, JD-004, has received Orphan Drug Designation for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD).
The company is planning to advance its ADPKD programme into clinical development. It plans to continue collaborating with the FDA and the nephrology community to move towards delivering an anti-inflammatory treatment option.
The product has been safely tested in patients with osteoarthritis and rheumatoid arthritis.
Lenard Lichtenberger, PhD, Chief Scientific Officer, said, "Receiving Orphan Drug Designation is a significant milestone for J & D Pharmaceuticals. This designation underscores the urgent need for innovative therapies for ADPKD patients and strengthens our commitment to developing solutions that can transform the lives of those affected by this debilitating condition."
GSK to acquire trispecific T cell-engager from Chimagen for multiple myeloma
FDA grants Priority Review to Genentech's Enspryng for MOGAD
Kali Therapeutics' KT501 Investigational New Drug application cleared by US FDA
Antengene's Phase I study of ATG-201 in B cell-related autoimmune diseases approved in Australia
Alfasigma to acquire Nordic Pharma, expanding specialty care portfolio
European Commission approves RINVOQ for severe alopecia areata
AbCellera and Vertex agree collaboration to develop multispecific T-cell engagers